Arsenal Medical

Arsenal Medical is a clinical-stage medical device company based in Watertown, Massachusetts, that develops proprietary biomaterials and localized therapies to treat complex neurovascular conditions, acute trauma, and postpartum hemorrhage. The organization operates with an estimated 10 to 50 employees and maintains an intellectual property portfolio consisting of 38 issued patents alongside 12 peer-reviewed scientific papers. The enterprise has secured over $65 million in non-dilutive funding and research grants from prominent government partners, including the U.S. Department of Defense, DARPA, and the National Institutes of Health. Backed by venture capital equity from institutional investors such as Polaris Partners, the company recently achieved FDA breakthrough device status for its ResQFoam hemorrhage control product and completed first-in-human clinical studies for its NeoCast embolic material. Arsenal Medical was originally founded in 2005 by Carmichael Roberts, Robert Langer, and George Whitesides.

# Arsenal Medical: High-Level Overview

Arsenal Medical is a clinical-stage medical device company developing innovative biomaterials to address critical unmet needs in trauma care and neurovascular treatment.[1] Founded in 2005 and based in Waltham, Massachusetts, the company has raised $44.52M and operates with a mission-driven focus on transforming how medical devices are designed—starting from materials science rather than repurposing existing solutions.[1][2]

The company serves the healthcare sector with two lead products: ResQFoam™, an expanding foam designed to control life-threatening abdominal hemorrhage in trauma patients, and NeoCast™, an injectable embolic material for treating chronic subdural hematomas and hypervascular brain tumors.[2][3] Arsenal addresses two critical gaps in medicine: field-deployable solutions for non-compressible hemorrhage (a leading cause of preventable death after injury) and effective treatments for complex neurovascular conditions where traditional approaches fall short due to vascular anatomy.[4]

# Origin Story

Arsenal Medical was founded in 2005 by Carmichael Roberts (serial entrepreneur-investor), Robert Langer, and George Whitesides—luminaries in materials science, drug delivery, and biotech who previously revolutionized fields like clean energy and founded companies including Moderna and Genzyme.[2][5] The founding vision emerged from a deceptively simple question: rather than repurposing household materials (as early medical device pioneers did with sausage casings for artificial kidneys), could chemistry and material science be harnessed to design purpose-built devices from the molecule up?[4]

The company traces its intellectual roots to academic rigor in materials science combined with entrepreneurial execution. Under current President and CEO Dr. Upma Sharma, who began as a research scientist and progressed through regulatory, clinical, and business functions, Arsenal has validated its scientific approach through peer-reviewed literature and secured non-dilutive funding from prestigious sources including DARPA, the National Cancer Institute, National Heart, Lung, and Blood Institute, and the Department of Defense.[4][5]

# Core Differentiators

• Novel biomaterial design philosophy: Rather than modifying existing materials, Arsenal creates bespoke biomaterials engineered for specific clinical needs, representing a fundamental departure from traditional medical device development.[4]

• FDA breakthrough device designation: ResQFoam has been recognized as a breakthrough device by the FDA, signaling regulatory validation of its clinical significance.[2][3]

• Deep clinical penetration technology: NeoCast's shear-responsive design enables preferential flow to the deepest vessels first, reaching previously inaccessible areas in complex vascular structures.[6]

• Diverse non-dilutive funding: The company has secured backing from government agencies (DoD, DARPA, NIH) and life sciences centers, reducing dilution while validating scientific merit across multiple institutional review bodies.[5]

• Founder pedigree and expertise: The founding team's track record in building transformative biotech companies (Moderna, Genzyme) combined with world-class materials science credentials provides credibility and operational experience.[2][5]

# Role in the Broader Tech Landscape

Arsenal Medical operates at the intersection of two powerful trends: the biomaterials revolution in healthcare and the shift toward precision medicine for previously intractable conditions. The company exemplifies how rigorous materials science—traditionally applied in clean tech and pharmaceuticals—can be systematically applied to medical devices, a sector historically dominated by incremental engineering improvements rather than fundamental material innovation.

The timing is critical: trauma care and neurovascular treatment represent massive, underserved markets where current solutions are inadequate. Non-compressible hemorrhage remains a leading preventable cause of death, while chronic subdural hematomas and hypervascular tumors lack fully effective treatment options. Arsenal's approach directly addresses these gaps by designing materials that solve specific clinical problems rather than forcing clinical problems into existing material constraints.

The company's success could influence the broader medtech ecosystem by demonstrating that venture-backed, materials-science-first approaches can compete with traditional device manufacturers, potentially attracting more fundamental science talent and capital into medical device innovation.

# Quick Take & Future Outlook

Arsenal Medical stands at an inflection point. With ResQFoam's FDA breakthrough designation and NeoCast progressing through clinical trials (the EMBO-02 study for chronic subdural hematoma treatment completed initial cohort enrollment in February 2025), the company is transitioning from proof-of-concept to clinical validation.[1][2] The next critical milestones will be regulatory approvals and market adoption—demonstrating that superior biomaterial design translates to clinical and commercial success.

The broader trajectory suggests that as healthcare systems increasingly prioritize outcomes and cost-effectiveness, purpose-engineered biomaterials will gain competitive advantage over legacy solutions. Arsenal's founders' track record in building category-defining companies, combined with the company's scientific rigor and regulatory momentum, positions it as a potential category leader in biomaterial-driven medical devices. The question ahead is whether Arsenal can scale manufacturing and clinical adoption while maintaining the innovation velocity that defines its early stage—a challenge that will determine whether this materials-science-first philosophy becomes a new paradigm in medtech.